2017. Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s10. DOI:https://doi.org/10.25251/skin.1.supp.9.